Relationship between 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism and methotrexate related toxicity in patients with autoimmune diseases receiving folic acid supplementation.
Speletas
M
M
Papadopoulos
N
N
Daiou
C
C
Katodritou
E
E
Pavlitou-Tsiontsi
A
A
Galanopoulou
V
V
D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2) / Q000235:genetics*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018501:Antirheumatic Agents / Q000009:adverse effects; D001327:Autoimmune Diseases / Q000188:drug therapy*; D019587:Dietary Supplements; D004347:Drug Interactions; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D012216:Rheumatic Diseases / Q000188:drug therapy
D018501:Antirheumatic Agents; D005492:Folic Acid; D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2); D008727:Methotrexate